Facts About Flu
Facts About Flu

According to the CDC,

Flu places a significant burden on the health and economy of the United States1-3

In children ≤17 years of age, the impact of flu remains significant1,4

Burden of Influenza Burden of Influenza

Annual CDC flu vaccination goals have not been reached

The CDC’s Healthy People 2030 objective for annual flu vaccination rate in children ages 6 months-17 years is 70%5

Approximately 36.2% of children in these age groups went unvaccinated6

2019-2020 flu vaccine estimated coverage rates for children by age group7

2019-2020 Flu Vaccine Estimated Coverage Rates for Children by Age Group 2019-2020 Flu Vaccine Estimated Coverage Rates for Children by Age Group

Additional options for influenza vaccination of children, including use of noninjectable vaccines, may help improve coverage8

The CDC states that overall vaccination coverage remains suboptimal, particularly in adults 18-64 years of age6

2019-2020 flu vaccination estimated coverage rates for adults by age group9

2019-2020 Flu Vaccine Estimated Coverage Rates for Adults by Age Group 2019-2020 Flu Vaccine Estimated Coverage Rates for Adults by Age Group

CDC recommends annual flu vaccination for everyone 6 months and older with any licensed, age-appropriate flu vaccine (IIV, RIV4, or LAIV4), with no preference expressed for any one vaccine over another.10

CDC=Centers for Disease Control and Prevention; IIV=inactivated influenza vaccine; LAIV4=quadrivalent live attenuated influenza vaccine; RIV4=quadrivalent recombinant influenza vaccine.

*Estimated number.


  • FLUMIST QUADRIVALENT is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist
  • Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • FLUMIST QUADRIVALENT has not been studied in immunocompromised persons
  • The safety of FLUMIST QUADRIVALENT in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine
  • FLUMIST QUADRIVALENT may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported were runny nose or nasal congestion in persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FLUMIST QUADRIVALENT, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FLUMIST QUADRIVALENT, 44% reported runny nose or nasal congestion and 19% reported sore throat

FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.

Please see full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.